{
    "name": "nadofaragene firadenovec",
    "comment": "Rx",
    "other_names": [
        "Adstiladrin",
        "nadofaragene firadenovec-vncg"
    ],
    "classes": [
        "Biological Response Modifiers",
        "Gene Therapies",
        "Oncologics"
    ],
    "source": "https://reference.medscape.com/drug/adstiladrin-nadofaragene-firadenovec-4000046",
    "pregnancy": {
        "common": [
            "No adequate and well-controlled studies have been conducted in pregnant females",
            "Advise pregnant females of potential risk to a fetus",
            "Verify pregnancy status in females of reproductive potential before initiating "
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 6 months following last dose",
                    "Males with female partners of reproductive potential: Use effective contraception during treatment and for 3 months following last dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding drug presence in human milk, effects on breastfed infants, or effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity reactions to interferon alfa or to any component of the product"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Risk of muscle invasive or metastatic bladder cancer with delayed cystectomy",
                    "description": [
                        "Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer",
                        "Risk of developing muscle-invasive or metastatic bladder cancer increases the longer cystectomy is delayed in the presence of persisting CIS",
                        "Median time from persistence or recurrence of CIS to cystectomy in these patients was 235 days ",
                        "If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy"
                    ]
                },
                {
                    "type": "Risk of disseminated adenovirus infection",
                    "description": [
                        "Owing to possible presence of low levels of replication-competent adenovirus in drug, immunocompromised persons, including those receiving immunosuppressant therapy, may be at risk for disseminated adenovirus infection",
                        "Avoid exposing immunosuppressed or immune-deficient individuals to nadofaragene firadenovec"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and nadofaragene firadenovec both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Glucose increased",
            "percent": "38"
        },
        {
            "name": "all grades",
            "percent": "33"
        },
        {
            "name": "Instillation site discharge",
            "percent": "30"
        },
        {
            "name": "Triglycerides increased",
            "percent": "24"
        },
        {
            "name": "all grades",
            "percent": "20"
        },
        {
            "name": "Fatigue",
            "percent": "19"
        },
        {
            "name": "Bladder spasm",
            "percent": "17"
        },
        {
            "name": "Micturition urgency",
            "percent": "17"
        },
        {
            "name": "Hematuria",
            "percent": "16"
        },
        {
            "name": "Creatinine increased",
            "percent": "16"
        },
        {
            "name": "all grades",
            "percent": "16"
        },
        {
            "name": "Chills",
            "percent": "16"
        },
        {
            "name": "Dysuria",
            "percent": "15"
        },
        {
            "name": "Phosphate decreased",
            "percent": "3"
        },
        {
            "name": "all grades",
            "percent": "4"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "6"
        },
        {
            "name": "Pyrexia",
            "percent": "3"
        },
        {
            "name": "Glucose increased",
            "percent": "4"
        },
        {
            "name": "Grade",
            "percent": "1.9"
        },
        {
            "name": "or",
            "percent": "3"
        },
        {
            "name": "Triglycerides increased",
            "percent": "4"
        },
        {
            "name": "Grade",
            "percent": "1.4"
        },
        {
            "name": "or",
            "percent": "1.3"
        },
        {
            "name": "Phosphate decreased",
            "percent": "1.3"
        },
        {
            "name": "Grade",
            "percent": "1.3"
        },
        {
            "name": "or",
            "percent": "1.3"
        },
        {
            "name": "Coronary artery disease",
            "percent": "1.3"
        },
        {
            "name": "Acute coronary syndrome",
            "percent": "1.3"
        },
        {
            "name": "Atrial fibrillation",
            "percent": "0.6"
        },
        {
            "name": "Dehydration",
            "percent": "0.6"
        },
        {
            "name": "Hypoglycemia",
            "percent": "0.6"
        },
        {
            "name": "low blood sugar",
            "percent": "0.6"
        },
        {
            "name": "Syncope",
            "percent": "0.6"
        },
        {
            "name": "fainting",
            "percent": "0.6"
        },
        {
            "name": "Heart failure",
            "percent": null
        },
        {
            "name": "Pericarditis",
            "percent": null
        },
        {
            "name": "Brain edema",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        },
        {
            "name": "Bile duct stone",
            "percent": null
        },
        {
            "name": "Sepsis",
            "percent": null
        },
        {
            "name": "Hemoglobin decreased",
            "percent": null
        }
    ]
}